CBLIF and psoriasis: A study with 109 patients of Spain diagnosed with psoriasis showed an association between patients carrying the TT genotype of the TNF-1031 polymorphism and anti-TNF response at 3 and 6 months (3-month PASI 75:90.8% vs. 75.7% (p = 0.047); 6 month PASI 75:85.5% vs. 65.7% (p = 0.038)); specifically, INF achieved the highest response at 3 months (PASI 75:84.2% vs. 42.9%, p = 0.024; PASI 90:73.